HIV-1 gp120 Upregulates Brain-Derived Neurotrophic Factor (BDNF) Expression in BV2 Cells via the Wnt/β-Catenin Signaling Pathway

J Mol Neurosci. 2017 Jun;62(2):199-208. doi: 10.1007/s12031-017-0931-z. Epub 2017 May 30.

Abstract

HIV-1 gp120 plays a critical role in the pathogenesis of HIV-associated pain, but the underlying molecular mechanisms are incompletely understood. This study aims to determine the effect and possible mechanism of HIV-1 gp120 on BDNF expression in BV2 cells (a murine-derived microglial cell line). We observed that gp120 (10 ng/ml) activated BV2 cells in cultures and upregulated proBDNF/mBDNF. Furthermore, gp120-treated BV2 also accumulated Wnt3a and β-catenin, suggesting the activation of the Wnt/β-catenin pathway. We demonstrated that activation of the pathway by Wnt3a upregulated BDNF expression. In contrast, inhibition of the Wnt/β-catenin pathway by either DKK1 or IWR-1 attenuated BDNF upregulation induced by gp120 or Wnt3a. These findings collectively suggest that gp120 stimulates BDNF expression in BV2 cells via the Wnt/β-catenin signaling pathway.

Keywords: BDNF; HIV-1 gp120; Microglia; Wnt/β-catenin signaling.

MeSH terms

  • Animals
  • Brain-Derived Neurotrophic Factor / genetics
  • Brain-Derived Neurotrophic Factor / metabolism*
  • Cell Line
  • HIV Envelope Protein gp120 / pharmacology*
  • Mice
  • Microglia / drug effects
  • Microglia / metabolism
  • Up-Regulation
  • Wnt Signaling Pathway*
  • Wnt3A Protein / genetics
  • Wnt3A Protein / metabolism
  • beta Catenin / metabolism

Substances

  • Brain-Derived Neurotrophic Factor
  • HIV Envelope Protein gp120
  • Wnt3A Protein
  • Wnt3a protein, mouse
  • beta Catenin